Severity and Quality of Life of Migraine among Patients on Migraine Prophylactic Medications: A Cross Sectional Study at King Abdulaziz University Hospital, Jeddah
Abstract
Background: Migraine was found to impact the patients’ quality of life, resulting in significant disability. Objectives: To assess the quality of life (QoL) of migraine patients on migraine prophylactic medications at King Abdulaziz University Hospital, Jeddah, Kingdom of Saudi Arabia. Methods: A cross-sectional study was conducted and data were collected through patient interviews and from hospital records. A questionnaire was used to collect demographic data, patient medical history related to migraine and a Migraine Specific Quality of Life Questionnaire (MSQ) was used to assess QoL. A Migraine Disability Assessment Score (MIDAS) was used to assess the number of days patients missed or lost productivity and any migraine related disability. Results: 64.2% of respondents had been diagnosed with migraine for more than 5 years, and 35.8% were diagnosed between the ages of 18 and 29. 5.7% were using a prophylactic supplement or herb, while the majority (56.6%) were not on any current prophylactic. About 45.3% and 26.4% respectively, had little or no disability and mild disability while 15.1% and 13.2% of the study group, respectively, had moderate and severe disabilities. Participants taking Ketamine and having only one attack per month had significantly higher mean MSQ scores, suggesting a higher quality of life. Whereas, participants taking Topamax and having only one attack monthly had a much higher proportion of those who had little or no disability. Conclusion: 15.1% and…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.